Best of ASCO - 2014 Annual Meeting

 

Welcome

Immunobiology

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Accurately identifying neoantigens for therapeutic and diagnostic use in immuno-oncology.

Sean Michael Boyle

e24148

Alteration of immune markers in the tumor microenvironment after chemoradiation for rectal cancer.

Prashant Mukesh Jani

e24146

Association of 18F-FDG uptake on PET with PD-L1 expression in patients with non-small cell lung cancer.

Kyoichi Kaira

e24138

Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).

Douglas Kanter Marks

12057

Association of expression of toll-like receptors 2 and 9 in circulating leukocytes with infection and death risk in elderly with cancer.

Guacyra Magalhaes Pires

e24142

Association of loss of adaptive PD-L1 expression with upregulation of PBRM1 chromatin regulator in melanoma.

Daniel Sanghoon Shin

12012

Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence.

Kroopa Joshi

12009

Characterization of shared repertoires in tumor infiltrating lymphocytes.

Mark Woodcock

e24149

Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.

Frank A. Sinicrope

e24127

Colorectal cancer characteristics and outcomes after solid organ transplantation.

Amit Merchea

e24131

Computer extracted features of cancer nuclei from H&E stained tissues of tumor predicts response to nivolumab in non-small cell lung cancer.

Xiangxue Wang

12061

Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.

Kevin Lee Min Chua

12056

Differences in density of tumor infiltrating immune cells and its prognostic role in five different malignancies.

Carlos Castaneda Altamirano

e24139

Effects of neoadjuvant chemotherapy on immune microenvironment and clinical outcomes in locally advanced gastric cancer.

Yue Yu

e24133

Epigenetic regulation of immunotherapy and T cell exhaustion by tractinostat in a syngeneic CT26 colon cancer mouse model.

Hao Shen

e24122

Evaluation of IL-2 in sustaining the PD-L1 blockade‒mediated reinvigoration of T cell function in melanoma.

Hui Yan

e24145

Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models.

Tarik Silk

12060

Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).

Ila Datar

12015

Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.

Ameen Abdulla Salahudeen

12014

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.

Jonathan Back

12053

High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.

Gizem Oner

e24136

Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).

Lee Chun Park

12050

Immunoprofiling in intrahepatic cholangiocarcinoma (IHCC).

Roberto Carmagnani Pestana

12049

In Vivo validation of novel p53-independent therapeutic modalities for small cell lung cancer (SCLC).

Kai Kang

e24141

Interrogating PI3K to induce PD-L1 expression in oral carcinoma.

Sanjay Chandrasekaran

e24119

Isolation of CD4+ T cells specific for neoantigens created by recurrent driver mutations in non-small cell lung cancer (NSCLC) and melanoma.

Joshua Veatch

12054

Linking MAPK inhibition and the response to TNF in melanoma.

Sanjay Chandrasekaran

e24143

Modeling of the tumor microenvironment to highlight nonlinear interactions between chemotherapeutic response and macrophage polarization state.

Louis Talbert Curtis

e24120

Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.

Kyung Hwan Kim

e24115

Multispectral quantitative analysis of tumor-infiltrating lymphocyte (TIL) in triple negative breast cancer.

Tomoharu Sugie

e24123

PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).

Jennifer Bordeaux

12059

PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases.

Benjamin Y. Lu

e24116

Prognostic value of histopathological tumor-stroma ratio and a stromal gene expression signature in human solid tumors.

Jakob Nikolas Kather

e24113

Right tumor, right time: Systematic methodology for fiducial marker placement to achieve reliable and reproducible image guided (IG) delivery of intratumoral immunotherapy into deep/visceral (D/V) lesions and target-lesion imaging follow-up.

Gregory Woodhead

e24137

Role of CD4 cells in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling.

Siwen Hu-Lieskovan

12013

Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer.

Marzia Del Re

e24128

Survival and immune analysis of radium-223 in patients with metastatic prostate cancer.

Joseph W. Kim

e24144

Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.

Hua-Xin Gao

12055

T cell receptor beta immune repertoire sequencing in FFPE preserved samples: Increasing flexibility and applicability for immuno-oncology studies.

Lauren Miller

e24121

Tetrahydrouridine/decitabine/5-azacytidine for non-cytotoxic epigenetic-immunotherapy of NSCLC in vivo.

Kai Kang

e24134

The effect of doxorubicin on the cancer-testis antigens transcription.

Denis S. Kutilin

e24117

The impact of chemotherapy on the immunophenotype of peripheral blood lymphocytes and survival in patients with non-small cell lung cancer.

Mohanad Aldarouish

e24125

The TRANSERI study: Effect of eribulin (E) on circulating TGFβ and TNFα in metastatic breast cancer (mBC) patients (pts)—Relationship with outcome.

Ornella Garrone

e24129

TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes.

Ed Kheder

12052

Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?

Monica Khunger

12058

Tumor-associated macrophages: CD206 and CD68 expression and patient outcomes in locally advanced breast cancer.

Chelsea Nicole Williams

e24130